Ten stocks boasted strong gains on Tuesday, outperforming a lackluster performance on Wall Street, as investors continued to digest a flurry of strong corporate earnings. Of the 10 stocks, four notably notched new record highs.
In contrast, Wall Street’s three major indices finished mixed, with the Dow Jones the only gainer, up 0.11 percent. The S&P 500 and the Nasdaq both dropped by 0.16 percent and 0.71 percent, respectively.
In this article, we spotlight the 10 big names that performed well on Tuesday and break down the reasons behind their gains.
To come up with the list, we considered the stocks with a $2 billion market capitalization and 5 million shares in trading volume.
The New York Stock Exchange building. Photo by Дмитрий Трепольский on Pexels
10. Wolfspeed Inc. (NYSE:WOLF)
Wolfspeed rallied for a 6th consecutive day on Tuesday to reach a fresh all-time high, as investors resumed buying positions after posting improved earnings in the third quarter of fiscal year 2026.
In intra-day trading, the stock climbed to its highest price of $53.98 before trimming gains to end the session just up by 6.78 percent at $53.72 apiece.
In an updated report, Wolfspeed Inc. (NYSE:WOLF) said that it slashed its net losses by 58 percent in the three months ending March 2026, at $119.9 million versus $285.5 million in the same period last year.
Revenues declined by 18.9 percent to $150.2 million from $185.4 million year-on-year, but fell within its earlier guidance of $140 million to $160 million.
CEO Robert Feurle said that Wolfspeed Inc. continued to make meaningful progress against its priorities, improving long-term growth trajectory and financial flexibility to execute strategic priorities.
Looking ahead, the company expects to generate revenues of $140 million to $160 million for the fourth quarter ending June 2026, or a decline of 18.8 percent to 29 percent from the $197 million posted in the same comparable period.
Operating expenses are projected to remain flat on a quarter-on-quarter basis, while gross margins are expected to end in the red.
9. Alignment Healthcare Inc. (NASDAQ:ALHC)
Alignment Healthcare bounced back by 7.11 percent on Tuesday to finish at $18.38 apiece, as investors positioned portfolios ahead of business updates from its participation in a health conference this week, while digesting changes in its leadership composition.
In a notice on its website, Alignment Healthcare Inc. (NASDAQ:ALHC) said that it would participate in the BofA Securities Health Care Conference on Wednesday, May 13, where investors are expected to watch out for business updates and guidance.
In other news, Alignment Healthcare Inc. announced changes to its leadership, with John Kao now assuming chairmanship, in addition to his role as CEO. He will replace Joseph Konowiecki, who transitioned as vice chairman and executive vice president of corporate affairs for the company.
Kao will continue to lead the company day-to-day, maintaining continuity of strategy and execution.
“Alignment is making strong progress as we enter our next phase of growth. Taking on the role of Chairman allows me to work even more closely with the Board as we focus on disciplined execution, long-term value creation, and delivering for the seniors and providers we serve,” he noted.
Meanwhile, Alignment Healthcare Inc. welcomed Shane Hochradel as its new chief operations officer. He brings experience leading complex healthcare operations across Medicare, Medicaid, and commercial businesses, most recently at Elevance Health and previously at UnitedHealth Group and Highmark Health.
As COO, Hochradel will oversee enterprise operations, providing leadership across markets and functions.
8. Oscar Health Inc. (NYSE:OSCR)
Oscar Health extended its winning streak to a 5th straight session on Tuesday to hit a seven-month high, as investors resumed buying positions following a stellar first-quarter performance, having more than doubled its net income during the period.
At intra-day trading, the stock climbed to as much as $23.76, or just 4-cents shy of its 52-week high of $23.80 in October 2025. It trimmed a few cents toward the end to be just up by 7.86 percent at $23.73 apiece.
The rally was primarily driven by continued optimism following news that its net income soared by 147 percent to $679 million from $275 million in the same period last year.
Revenues increased by 52 percent to $4.6 billion from $3.05 billion in the same period last year, thanks to higher rates and membership.
Following the results, Oscar Health Inc. (NYSE:OSCR) reaffirmed its outlook of $18.7 billion to $19 billion in revenues for full-year 2026, or an implied growth of 60 percent to 62 percent from the $11.7 billion posted in 2025.
It also expects to incur operating income of $250 million to $450 million, or a reversal of $396 million operating loss year-on-year.
7. Aramark (NYSE:ARMK)
Aramark bounced back by 8.64 percent on Tuesday to hit an all-time high, as investors increased their exposure following news that it is making a foray into the hyperscale AI data center market in a bid to capture a share in the rapidly growing sector.
In intra-day trading, Aramark (NYSE:ARMK) climbed to its highest price of $51.17 before trimming gains to finish the session just up by 8.64 percent at $48.41 apiece.
In an updated report, Aramark said that it recently launched the Aramark Nexus, a new platform delivering hospitality and workforce support services for hyperscale AI data centers and other large-scale, complex, and often remote operating environments.
It said that a new multi-year agreement with a top global hyperscaler is underway, and that it expects a significant pipeline of growth opportunities for the said business.
In other news, Aramark reported stellar earnings in the second quarter of fiscal year 2026, with net income attributable to shareholders jumping by 65 percent to $101.95 million from only $61.85 million in the same period last year.
Revenues increased by 14 percent to $4.9 billion from $4.28 billion year-on-year, primarily led by broad-based net new business and base business growth in food and support services in both the US and international.
Meanwhile, operating income grew by 26 percent as enhanced technology capabilities boosted productivity gains.
6. Legend Biotech Corp. (NASDAQ:LEGN)
Legend Biotech rebounded by 10.48 percent on Tuesday to finish at $28.26 apiece, as investors cheered its strong performance in the first quarter of the year, having slashed its net losses and propelled its revenues, thanks to strong sales from its cancer treatment, Carvykti.
In an updated report, Legend Biotech Corp. (NASDAQ:LEGN) said that it narrowed its net loss by 46 percent to $54.3 million from $101 million in the same period last year.
Total revenues increased by 56 percent to $305.1 million from $195 million year-on-year, thanks to a 62 percent jump in net trade sales from Carvykti.
“We believe Carvykti’s continued adoption and strong year‑over‑year growth reinforce our leadership in BCMA CAR‑T and the strength of our underlying operating model,” Legend Biotech Corp. CEO Ying Huang said
“As scale continues to build, we are seeing operating leverage translate into improving margins, supporting our path toward sustainable profitability. This continued progress is enabling us to advance our broad pipeline of cell therapy programs and extend the impact of our platform to address unmet needs for patients across multiple indications.”
Carvykti is now available in 18 countries, having been launched recently in Italy, Poland, Czech Republic, and Australia.
5. Insmed Incorporated (NASDAQ:INSM)
Insmed climbed by 11.66 percent on Tuesday to close at $116 apiece, as investors resorted to bargain-hunting after touching a 10-month low the day prior.
On Monday, it can be recalled that the stock fell below the $100 territory, touching $98.90 at intra-day trading—its lowest price over the last 10 months, dented by an earnings miss in the first quarter of the year.
Investors, however, took the drop as an opportunity to hunt for bargains on Tuesday, with Insmed Incorporated (NASDAQ:INSM) maintaining a “strong buy” recommendation from 16 analysts.
In the first quarter of the year, Insmed Incorporated slashed its net loss by 36 percent to $163 million from $256 million in the same period last year, as total revenues soared by 230 percent to $306 million from $92.8 million year-on-year, thanks to strong sales from its lung treatment, Brinsupri.
The therapy alone raked in $207.2 million in sales in the US, and $700,000 internationally.
“The trajectory of the Brinsupri launch continues to exceed our expectations, and we are especially encouraged by the positive topline results from the Encore Phase 3b study, which could enable us to extend our reach to even more patients. We remain focused on improving bronchiectasis diagnosis, expanding the Arikayce label, advancing our Phase 3 programs for TPIP, and progressing our early-stage pipeline, with the ambition of delivering meaningful innovation and improving the lives of patients with serious diseases,” said Insmed Incorporated CEO Will Lewis.
In other news, the company is set to present data from the Phase 3b study for Arikayce at the American Thoracic Society International Conference 2026 on May 17 to 20.
4. Sea Ltd. (NYSE:SE)
Shopee operator Sea Ltd. snapped a three-day losing streak on Tuesday, soaring 13.14 percent to close at $96.02 as investors cheered its strong earnings performance in the first quarter of the year.
In an updated report, Sea Ltd. (NYSE:SE) grew its net income by 6.7 percent to $438.2 million from $410.8 million in the same period last year.
Revenues soared by 46.6 percent to $7.097 billion from $4.841 billion year-on-year.
“We have had a strong start to the year. 2026 is a year where we are leaning in to deepen our competitive moats, while maintaining financial discipline. Our strong revenue growth reflects the effectiveness of these investments, and we are already seeing unit economics start to improve for some of these initiatives,” Chairman and CEO Forrest Li said.
Shopee alone recorded $4 billion in gross orders during the quarter, marking a jump of 29.3 percent year-on-year. Revenues stood at $5.1 billion, or 45.1 percent higher.
“Shopee delivered another record-setting quarter, achieving new highs in GMV, gross order volume, and revenue while maintaining financial discipline,” Li said.
Meanwhile, revenues from Monee increased by 57.8 percent to $1.2 billion, thanks to strong consumer and SME credit business. Garena, on the other hand, raked in $696.6 million, marking a 40.6 percent increase from the same period. Bookings finished at $931.4 million, up 20.1 percent year-on-year.
3. Venture Global Inc. (NYSE:VG)
Venture Global rallied for a second day on Tuesday, surging 14.20 percent to close at $13.27 apiece, as investors cheered a double-digit growth in both net income and revenues for the first quarter of the year, while markedly raising its growth outlook for 2026.
In a statement, Venture Global Inc. (NYSE:VG) said that it grew its net income by 23 percent to $488 million from $396 million in the same period last year, primarily driven by higher operating income of $71 million, thanks to higher LNG sales volume from the Plaquemines site.
Revenues climbed 59 percent to $4.599 billion from $2.894 billion year-on-year.
“The first quarter of 2026 was a dynamic, and at times volatile period for the global LNG market, and we are proud that our company has played a critical role in helping maintain supply stability. Venture Global continues to deliver reliable US energy to our customers, while generating strong financial results for our shareholders,” Venture Global Inc. CEO Mike Sabel said.
“We are making significant progress on construction at our third facility, CP2, including raising the roofs of our first two LNG tanks this quarter and successfully closing an $8.6 billion FID for Phase II of that project. We are continuing the safe startup and commissioning of Plaquemines LNG and are reaffirming our expectation of achieving Phase I commercial operations later this year. As the market navigates the ongoing impacts of the conflict in the Middle East, Venture Global remains focused on the safe, disciplined execution of our operating, commissioning, and construction plans,” he noted.
For the full-year period, Venture Global Inc. raised its consolidated adjusted EBITDA guidance to a range of $8.2 billion to $8.5 billion, versus the $5.2 billion to $5.8 billion previously.
2. Quantum Computing Inc. (NASDAQ:QUBT)
Quantum Computing climbed by 15.72 percent on Tuesday to finish at $11.78 apiece, as investor sentiment was boosted by the 9,364 percent jump in its revenues in the first quarter of the year, thanks to the share of newly acquired companies.
In an updated report, Quantum Computing Inc. (NASDAQ:QUBT) said that it incurred $3.69 million in revenues during the period, a marked jump from only $39,000 in the same period last year, driven primarily by its acquisition of Luminar Semiconductor Inc., and to a lesser extent, NuCrypt LLC.
On the other hand, Quantum Computing Inc. swung to a net loss of $4.05 million from a $16.98 million net income in the same comparable period, primarily due to higher operating expenses, coupled with the decrease in non-cash gain on the mark-to-market of the company’s derivative liability, which relates to warrants issued for the merger with Qphoton in June 2022.
Looking ahead, the photonics firm posted an upbeat outlook for its business amid expected demand growth to support faster and more efficient data processing.
“It is becoming increasingly clear that photonics will be a critical component of future technological advancements given its low power consumption and ability to operate at room temperature. During the first quarter we strengthened our position in this space, and made significant progress in advancing our technology roadmap and continued to grow our commercial momentum,” Quantum Computing Inc. CEO Yuping Huang said.
1. Ralliant Corp. (NYSE:RAL)
Ralliant Corp. extended its winning streak to a third consecutive day on Tuesday, to hit a new all-time high, after beating its own revenue expectations for the first quarter of the year.
In intra-day trading, the stock surged to its highest price of $60.14 before trimming gains to end the session just up by 19.37 percent at $59.16 apiece.
In an updated report, Ralliant Corp. (NYSE:RAL) said that revenues ended at $535 million, higher by 11 percent than the $481.8 million in the same period last year and exceeding earlier guidance of $508 million to $522 million.
The jump was primarily driven by growth in revenues from both sensors and safety systems and test and measurement (T&M) segments, up 11 percent and 12 percent, respectively.
Net earnings, on the other hand, fell by 30.8 percent to $44.2 million from $63.9 million in the same period last year amid lower operating profit.
Earnings before income taxes declined by 27.8 percent to $52.9 million from $73.3 million year-on-year.
Following the results, Ralliant Corp. raised its revenue growth expectations for full-year 2026 to a range of $2.185 billion to $2.245 billion, versus $2.1 billion to $2.2 billion previously.
Adjusted EPS was also pegged at $2.53 to $2.69, higher than the $2.22 to $2.42 projected earlier.
For the second quarter alone, Ralliant Corp. expects revenues to be in the range of $540 million to $556 million, or an implied increase of 7.3 percent to 10.5 percent versus the $503 million posted in the same period last year.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
